GeneDx Holdings (NASDAQ: WGS) stock surged 5.43% in intraday trading on Tuesday following the release of its impressive third-quarter financial results for 2025. The company's performance significantly exceeded analyst expectations, particularly in terms of revenue and adjusted earnings per share.

According to the financial report, GeneDx posted Q3 revenue of $116.7 million, substantially outperforming the IBES estimate of $104.1 million. This represents a 52% year-over-year growth. The company's adjusted earnings per share came in at $0.49, beating the consensus estimate of $0.39. Notably, exome and genome test revenue grew by 65% year-over-year, driven by a 33% increase in test volumes.

In light of the strong performance, GeneDx raised its full-year 2025 revenue guidance to between $425 million and $428 million, up from the previous range of $400 million to $415 million. The company also expects 53% to 55% growth in exome and genome revenue for the full year. Additionally, GeneDx announced it had received FDA Breakthrough Device Designation for its ExomeDx™ and GenomeDx™ tests, underscoring its innovative leadership in the genomics space. The market's enthusiastic response to these results and outlook improvements reflects growing investor confidence in GeneDx's financial health and growth trajectory in the competitive genomics and diagnostics sector.